SOURCE: MediJane Holdings Inc.

May 06, 2014 06:20 ET

MediJane Holdings Finalizes Agreement to Distribute Canna-Mist Sublingual Cannabinoid Spray

LONGMONT, CO--(Marketwired - May 6, 2014) - MediJane Holdings Inc. (OTCQB: MJMD) ("MediJane" or "MJMD" or the "Company") is pleased to announce that the "Canna-mist" sublingual cannabinoid spray, a product whose intellectual property was recently acquired by Phoenix Bio Pharm ("PBP"), will now be branded and sold under the MediJane name. The exclusive Canna-mist licensing and distribution agreement is another step forward for MediJane in expanding the suite of medical delivery systems available as the Company continues to expand and establishes itself as a leading medical cannabis company and as a brand.

Canna-mist is the brainchild of renowned botanist Pamela Clum, who recently joined the MediaJane Advisory Board. The sublingual spray delivery system allows for fast absorption of active cannabinoid alkaloids through the mucous system of the mouth and directly into the bloodstream for fast, effective, and smokeless symptom relief for the patient.

"The sublingual delivery system is one of the most effective and convenient drug delivery systems available for patients requiring regular self-medicated doses and, in the case of Canna-mist, provides the patient with fast relief from pain and inflammation," commented Lewis "Spike" Humer, Chairman of MediJane Holdings Inc. "Our sales, marketing, and manufacturing team is currently finalizing the product and we expect to have the newly branded MediJane "Canna-mist" ready for distribution in targeted states across the country in just a few weeks."

About MediJane Holdings Inc. (MJMD)

MediJane Holdings Inc. (MJMD) is in the business of marketing and distributing products within the medical marijuana industry, including transdermal patches, capsules, sublingual sprays, and other medical delivery systems. With sales offices opening in California and Colorado, and a planned expansion into a national footprint, MediJane products are designed to give doctors the ability to provide patients accurate and effective doses of cannabinoids to manage and treat pain and other specific illnesses. MediJane's lead product is an innovative non-drowsy "Daytime Pain plus CBD" oral capsule for the treatment of inflammation and chronic, neuropathic, arthritic, and back pain. This smokeless and accurate dose alternative is MediJane's initial launch into the chronic pain management market, which is estimated at over $45 billion annually in North America.

For more information, visit www.medijane.co

Disclaimer/Safe Harbor: Some information in this MediJane Holdings Inc. (MJMD) press release constitutes forward-looking statements or statements which may be deemed or construed to be forward-looking statements. The words "plan", "forecast", "anticipates", "estimate", "project", "intend", "expect", "should", "believe," and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to, known and unknown risks, uncertainties and other factors which could cause MJMD's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to MJMD herein are expressly qualified in their entirety by the above-mentioned cautionary statement. MJMD disclaims any obligation to update forward-looking statements contained in this press release, except as may be required by law.

Contact Information